120results about How to "Improve inflammatory response" patented technology

A method, and apparatus (10) for the controlled acceleration, and/or retardation of the body's inflammatory response generally comprises a foam pad (11) for insertion substantially into a wound site, a heating, a cooling pad (13) for application over the wound site (12), a wound drape (14) or sealing enclosure of the foam pad (11), the heating, and cooling pad (13) at wound site (12). The foam pad (11) is placed in fluid communication with a vacuum source for promotion of the controlled acceleration or retardation of the body's inflammatory response. The heating, and cooling provision controls the local metabolic function as part of the inflammatory response.

Disclosed herein are GNGN and G1/G2 antibodies that recognize and bind various FcRs and C1q. Also disclosed herein are glycan-optiminzed antibodies, predominantly of the GNGN or G1/G2 glycoform, with enhanced Fcγ receptor binding achieved through CHO, Nicotiana benthamiana and yeast manufacturing systems. Nucleic acids encoding these antibodies, as well as expression vectors and host cells including these nucleic acids are also disclosed herein. Methods and pharmaceutical compositions including the monoclonal antibodies are provided herein for the prevention and/or therapeutic treatment of viral infections, cancers and inflammatory diseases.

Methods for decellularizing mammalian tissue for use in transplantation and tissue engineering. The invention includes methods for simultaneous application of an ionic detergent and a nonionic detergent for a long time period, which may exceed five days. One method utilizes SDS as the ionic detergent and Triton-X 100 as the nonionic detergent. A long rinse step follows, which may also exceed five days in length. This long duration, simultaneous extraction with two detergents produced tissue showing stress-strain curves and DSC data similar to that of fresh, unprocessed tissue. The processed tissue is largely devoid of cells, has the underlying structure essentially intact, and also shows a significantly improved inflammatory response relative to fresh tissue, even without glutaraldehyde fixation. Significantly reduced in situ calcification has also been demonstrated relative to glutaraldehyde fixed tissue. Applicants believe the ionic and non-ionic detergents may act synergistically to bind protein to the ionic detergent and may remove an ionic detergent-protein complex from the tissue using the non-ionic detergent. The present methods find one exemplary use in decellularizing porcine heart valve leaflet and wall tissue for use in transplantation.

This document provides methods and materials related to regulating inflammatory pathways. For example, compositions and kits containing two or more of an anticholinesterase compound, a choline compound, and a carnitine compound and methods for using the compositions and kits described herein to support acetylcholine function to regulate one or more inflammatory pathways are provided.

The invention discloses a mutant human plasminogen kringle5 gene mK5 and an amplification primer of the mK5 gene, the mutant human plasminogen kringle5 gene modified by adding glutathione-S-transferase before the gene mK5, and a method for preparing protein mK5 recombinant protein of two gene codes, glutathioneS transferase (GST)-mK5 fusion protein and two proteins, wherein the mK5 gene and the GST-mK 5 gene can be applied to preparing medicaments for treating angiogenesis diseases. By the invention, the number of exogenous amino acid in the recombinant K5 protein molecules obtained by a gene engineering method is remarkably reduced, the K5 bioactivity of the obtained mK5 is improved, while the mK5 activity of the GST-mK5 fusion protein is maintained, the stability and water solubility of the protein are improved, the purification steps of an expressed product are simplified, and the purity of the product is improved.

A composition including a purified lipid cell-wall component or analog or derivative thereof and a suitable pharmaceutical carrier, medium, excipient or adjuvant is described. The composition is useful in prophylactic and therapeutic methods of treating a microbial infection in a subject, typically a mycobacterial infection such as tuberculosis, and immune disorders, inflammatory conditions and allergies in a subject, typically autoimmune diseases. It is also useful in diagnostic methods. The purified lipid cell-wall component is typically a purified mycolic acid or a mixture of purified mycolic acids from a bacterium which produces mycolic acids. The bacterium is from Mycobacterium, Corynebacterium, Nicardia or Rhodococcus.

The invention provides a magnesium alloy support coated with an acylated chitosan and polyester blend medicine coating. The support comprises a magnesium alloy bare support, the magnesium alloy bare support comprises at least two annular units formed by cylindrical rods in a sine 'peak-valley' shape, the annular units are connected on the axial direction through a link round rod to form a net structure, a blend medicine eluting type coating composed of acylated chitosan, polyester and medicine is coated on the surface of the magnesium alloy bare support. According to the invention, biological medical chitosan and polyester blend material are taken as a support surface coating to improve the biological compatibility, and the coating carries a medicine with restenosis resistance function, thereby the release speed of the medicine can be controlled, and the treatment purpose can be achieved. The magnesium alloy support coated with the acylated chitosan and polyester blend medicine coating possesses good collateral passing ability and flexibility, good radial supporting performance, and is capable of keeping perfusion smoothness of blood flow, effectively delaying the degradation time of the magnesium alloy support, controlling the release of the medicines, and reducing the incidence rate of acute and subacute thrombus after the support is implanted.

The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.

The present invention relates generally to methods and compositions for promoting wound healing in a subject. In particular, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in wound healing and compositions therefor which contain such compounds.

A novel formulation for the treatment of the many underlying inflammatory processes that cause dry eye syndrome. In particular, the formulation, which is orally administered includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin (PGE1). As used herein, the term “nutrient cofactor” refers to a compound that supports and enhances the conversion of linoleic acid to gamma-linolenic acid. Additionally, the formulation inhibits the production of pro-inflammatory compounds, as well as the growth of viral and bacterial pathogens of the three-layer tear film.

The invention provides a recyclable heart stent. The recyclable heart stent comprises a transmission assembly, an elastic mesh bag and a heating device, the transmission assembly comprises a catheterand a gasbag, the gasbag is fixedly arranged at one end of the catheter, the gasbag is sleeved with the elastic mesh bag, and the elastic mesh bag is made of a plurality of elastic tubes connected toeach other; the elastic tubes are filled with liquid metals, the heating device is used to heat the liquid metals in the elastic tubes, and in the recyclable heart stent, the elastic mesh bag confinesthe liquid metal to form a stent body; at the time of implantation, the structure of the elastic mesh bag is changed by inflating the gasbag, and the liquid metals are solidified so that the stent body maintains a specific shape structure; and at the time of recycling, the liquid metals are melt, the structure of the stent body is reduced by the inflating and the deflating of the gasbag and the elasticity of the elastic mesh bag, and then the stent body is brought out of the human bodies through the catheter. In addition, the liquid metals have the advantages of good bio-compatibility, anti-thrombus and anti-corrosion, and the liquid metals have no damage to the blood vessel wall so that the stimulation of blood vessels to cause the inflammatory reaction is avoided.

The present invention provides methods for treating animals having acute inflammatory conditions, including mastitis, by administering at least one p38 MAP kinase inhibitor. The present invention also provides methods for enhancing milk production and reducing milk discard in animals afflicted with acute inflammatory conditions by administering at least one, p38 MAP kinase inhibitor.

The invention discloses an application of a polypeptide or polypeptide derivatives capable of specific combination of TRB3 in preparation of drugs for treatment and/or prevention of rheumatoid arthritis; the polypeptide has the amino acid sequence being any one of sequences shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3; the polypeptide derivatives are chimeric peptides formed by connecting the polypeptide with cell membrane cell-penetrating peptides. The polypeptide or the polypeptide derivatives can be specifically combined with the TRB3 so as to block the interaction between the TRB3 and P62 proteins; and the peptide fragment derivatives Pep2-A1, Pep2-A2 and Pep2-A3 can treat or prevent various symptoms caused by rheumatoid arthritis.

The invention discloses application of a polypeptide for preparing medicine for treating the Alzheimer disease. The amino acid sequence is shown in SEQ ID NO:1. The polypeptide is an extracellular section 41-81 amino acids of a TREM2 receptor protein, and the nucleotide sequence is shown in SEQ ID NO:2. The polypeptide has the application that the microglial mediated inflammation reaction is promoted, apoptosis of microglial cells is restrained, the migration capability of microglial cells is enhanced, Abeta endocytosis and degradation of the microglial cells are promoted, the density of microglial cells inside a brain is increased, and Abeta amyloid plaque deposition inside the brain is lowered.

The invention relates to a traditional Chinese medicine composition for treating H1N1 flu induced viral lung injury. The composition is prepared from active ingredients and medically acceptable accessories, wherein the active ingredients are prepared from the following raw materials in parts by weight: 20-40 parts of roughhaired holly root, 10-20 parts of cablin potchouli herb, 5-15 parts of incised notopterygium, 10-20 parts of radix bupleuri, 8-20 parts of safflower, 10-20 parts of honeysuckle, 10-20 parts of divaricate saposhnikovia root, 10-20 parts of fineleaf schizonepeta herb, 9-20 parts of weeping forsythiae capsule, 5-15 parts of atratylodes rhizome, 8-20 parts of peach kernel and 0.35-1 part of artificial cow-bezoar. The traditional Chinese medicine composition has the effects of expelling evil and relieving exterior syndrome, detoxifying and facilitating lung, resolving phlegm and removing stasis, and the like, and can be applied to treatment of the H1N1 flu induced viral lung injury.

The invention provides a plant extract, and a preparation method and application thereof. The plant extract is obtained by extracting paniculate microcos leaves and guava leaves. The plant extract contains more than 60 percent by weight of flavone active substances. The plant extract can eliminate DPPH free radicals in vitro, can remarkably reduce the blood fat of mice fed with high-fat feed, can effectively improve mouse ear swelling inflammation caused by xylene and can protect rat acute myocardial damage caused by isoproterenol. The plant extract derives from pharmacological plants or medicinal and edible plants, is safe and reliable, does not have toxic or side effects, and can serve as novel anti-oxidation, anti-inflammation and fat-reducing medicines or health-care food.

Relating to the field of health, the invention relates to application of konjac flour to treatment and improvement of obesity. The invention consists of the following aspects: konjac flour intervenedanti-obesity effect; the influence of konjac flour intervention on inflammation; the regulating effect of konjac flour intervention on intestinal microorganisms; the influence of konjac flour intervention on colonic intestinal barrier function; the influence of konjac flour intervention on energy metabolism; and the correlation of konjac flour to intestinal microorganisms and obesity. The invention has the beneficial effects that: konjac flour not only can improve obesity-related indicators, but also can increase the diversity of intestinal microorganisms and improve the microbial community structure, promote the formation of beneficial bacteria and inhibit the growth of obesity-promoting bacteria.

An easy-to-carry easy-to-open packet finds use by athletes, mountain climbers and others engaged in physical activity. The packet has a fig paste based energy gel composition comprising glucose and natural fructose sugars which rapidly enter the blood stream. The energy gel optionally comprises ATP, which is released to the blood stream sublingually in the mouth without substantial degradation. The packet has a slit for the insertion of a belt, strap or carabineer. An inserted bonded tube on the packet's exterior edge has one end open and one end closed. The open end is in communication with energy gel within the packet. When the packet is pulled, the inserted bonded tube breaks, creating an open end that is placed between the teeth. Squeezing the packet discharges the gel into the mouth of the user.

The invention provides a preparing method and application of anti-chronic inflammation mesenchymal stem cells. The preparing method comprises the steps of culturing mesenchymal stem cells obtained through separation and extraction till the fusion rate reaches 70-80%, removing a culture medium in a mesenchymal stem cell culture dish, and flushing the mesenchymal stem cells with phosphate buffer; then adding a serum-free medium containing 50-200 ng/mL lipopolysaccharide; and adjusting the hypoxia state till oxygen content becomes 5-10%, and culturing the mesenchymal stem cells for 16-18 h in the hypoxia state. The anti-chronic inflammation mesenchymal stem cells can be used for treating chronic inflammation.

The present invention is concerned with the identification of compounds which increase the therapeutic index of chemotherapy drugs and which stimulate the growth of cancers, their use in the treatment of cancer and with certain novel compounds useful in such treatment.

The present invention provides compositions, methods, and kits for treating inflammation and regulating inflammatory responses including cytokine, prostanoid, prostaglandin, and growth factor expression.